TME Pharma N.V.
ALTME | Euronext Growth
Overview
Corporate Details
- ISIN(s):
- NL0015000YE1 (+1 more)
- LEI:
- 724500EPNADXWZ58U595
- Country:
- Germany
- Address:
- Max-Dohrn-Strasse 8-10, 10589 Berlijn
- Website:
- https://www.tmepharma.com/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma�s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.�
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-18 08:00 |
Inside Information Statement
Inside Information / Other news releases
|
English | 255.7 KB | |
| 2025-06-18 08:00 |
Inside Information Statement
Informations privilégiées / Autres communiqués
|
French | 287.8 KB | |
| 2025-05-21 08:00 |
Capital/Financing Update
Informations privilégiées / Autres communiqués
|
French | 329.1 KB | |
| 2025-05-21 08:00 |
Capital/Financing Update
Inside Information / Other news releases
|
English | 286.1 KB | |
| 2025-05-05 18:00 |
Directors' Dealings
Inside Information / Other news releases
|
English | 243.3 KB | |
| 2025-05-05 18:00 |
Directors' Dealings
Informations privilégiées / Autres communiqués
|
French | 255.1 KB | |
| 2025-05-05 08:00 |
Board/Management Change
Inside Information / Other news releases
|
English | 281.1 KB | |
| 2025-05-05 08:00 |
Inside Information Statement
Informations privilégiées / Autres communiqués
|
French | 287.8 KB | |
| 2025-04-25 18:00 |
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 351.1 KB | |
| 2025-04-25 18:00 |
Earnings Release
Inside Information / News release on accounts, results
|
English | 275.9 KB | |
| 2025-04-10 19:00 |
Capital/Financing Update
Informations privilégiées / Autres communiqués
|
French | 224.0 KB | |
| 2025-04-10 19:00 |
Capital/Financing Update
Inside Information / Other news releases
|
English | 208.3 KB | |
| 2025-03-28 18:00 |
Share Issue/Capital Change
Informations privilégiées / Autres communiqués
|
French | 269.4 KB | |
| 2025-03-28 18:00 |
Share Issue/Capital Change
Inside Information / Other news releases
|
English | 217.6 KB | |
| 2025-03-13 18:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 263.4 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Poxel | France | POXEL | |
|
PREDILIFE | France | ALPRE | |
|
PROSPEX ENERGY PLC | United Kingdom | PXEN | |
|
Prostatype Genomics AB | Sweden | PROGEN | |
|
Psych Capital Plc | United Kingdom | PSY | |
|
Pure Biologics S.A. | Poland | PUR | |
|
Puretech Health PLC | United States of America | PRTC | |
|
Purple Biotech Ltd. | Israel | PPBT | |
|
QLife Holding AB | Sweden | QLIFE | |
|
Quantum Genomics | France | ALQGC |